Augustine Therapeutics has successfully secured €78 million in Series A funding to further its development of novel therapies. The company is focused on inhibiting the HDAC6 enzyme to treat neuromuscular, neurodegenerative, and cardio-metabolic diseases. Their approach utilizes a unique, non-hydroxamate and non-hydrazide producing chemotype, which aims to be more selective and safer than previous HDAC6 inhibitors. The lead program, AGT-100216, is intended for the treatment of Charcot-Marie-Tooth Disease and will advance into clinical trials with this funding. The financing was led by Novo Holdings and Jeito Capital, with participation from existing and new investors.
Podcast creator page: http://santarovich.tilda.ws/
Support our podcast with your donations: https://paypal.me/OlgaSantarovich
